845751-59-9 Usage
General Description
7-Bromo-2H-indazole is a chemical compound with the molecular formula C7H5BrN2. It is an indazole derivative that contains a bromine atom attached to the 7th position of the indazole ring. 7-BroMo-2H-indazole is commonly used in pharmaceutical and research applications, particularly in the development of potential drug candidates. 7-Bromo-2H-indazole has been found to exhibit various biological activities, including potential anticancer and antimicrobial properties. It is also used as a building block in the synthesis of novel molecules for medicinal chemistry research. Overall, 7-Bromo-2H-indazole is a versatile chemical compound with potential applications in drug discovery and development.
Check Digit Verification of cas no
The CAS Registry Mumber 845751-59-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,4,5,7,5 and 1 respectively; the second part has 2 digits, 5 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 845751-59:
(8*8)+(7*4)+(6*5)+(5*7)+(4*5)+(3*1)+(2*5)+(1*9)=199
199 % 10 = 9
So 845751-59-9 is a valid CAS Registry Number.
845751-59-9Relevant articles and documents
Design and Synthesis of a Novel Series of Bicyclic Heterocycles As Potent γ-Secretase Modulators
Bischoff, Francois,Berthelot, Didier,De Cleyn, Michel,MacDonald, Gregor,Minne, Garrett,Oehlrich, Daniel,Pieters, Serge,Surkyn, Michel,Trabanco, Andres A.,Tresadern, Gary,Van Brandt, Sven,Velter, Ingrid,Zaja, Mirko,Borghys, Herman,Masungi, Chantal,Mercken, Marc,Gijsen, Harrie J. M.
supporting information, p. 9089 - 9106,18 (2020/10/15)
The design and the synthesis of several chemical subclasses of imidazole containing γ-secretase modulators (GSMs) is described. Conformational restriction of pyridone 4 into bicyclic pyridone isosteres has led to compounds with high in vitro and in vivo p
Indazole derivatives as CRF antagonists
-
Page/Page column 19, (2010/02/07)
This invention relates to compounds which are generally CRF-1 receptor antagonists and which are represented by Formula I or Formula II: wherein R3 is optionally substituted aryl or heteroaryl, R1 and R2 are as defined in
